Variable | n = 1323 |
---|---|
Age, median (IQR), years | 56 (45–68) |
Female, n (%) | 473 (36) |
Body mass index, median (IQR), kg/m2 | 23.9 (21.7–26.3) |
Diabetes, n (%) | 449 (34) |
Hypertension, n (%) | 1165 (88) |
Malignancy, n (%) | 202 (15) |
Kidney transplantation, n (%) | 238 (18) |
ACE-I or ARB treatment, n (%) | 675 (51) |
Spironolactone treatment, n (%) | 41 (3) |
CKD stagea, n (%) 3a/3b/4/5 | 450 (34)/471 (36)/337 (25)/65 (5) |
Creatinine, median (IQR), mg/dL eGFRcr, median (IQR), mL/min/1.73 m2 | 1.8 (1.5–2.3) 39 (27–48) |
Cystatin C, median (IQR), mg/L eGFRcys, median (IQR), mL/min/1.73 m2 | 1.7 (1.4–2.2) 38 (27–50) |
eGFRcr-cys, median (IQR), mL/min/1.73 m2 | 38 (27–49) |
Serum albumin, median (IQR), g/dL | 4.3 (4.0–4.5) |
PCR, median (IQR), μg/mg Cr | 0.50 (0.16–1.33) |